Home > Publications > Disease Control Priorities in Developing Countries >

45. The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight

Table 45.5: Incremental Cost-Effectiveness Ratios of a Multidrug Regimen by World Bank Region Compared with a Baseline of No Drug Treatment (2001 US$/DALY)

Incremental Cost-Effectiveness Ratios of a Multidrug Regimen by World Bank Region Compared with a Baseline of No Drug Treatment *(2001 US$/DALY)*
Region	35 percent risk	25 percent risk	15 percent risk	5 percent risk
East Asia and the Pacific	830	1,440	2,320	3,820
Europe and Central Asia	940	1,450	1,960	3,620
Latin America and the Caribbean	920	1,470	2,420	3,740
Middle East and North Africa	720	1,290	2,190	4,030
South Asia	670	1,250	1,932	3,020
Sub-Saharan Africa	610	1,170	1,920	2,960

Source: Authors' calculations.

Note: The regimen includes aspirin, a beta-blocker, a thiazide diuretic, an angiotensin-converting enzyme inhibitor, and a statin. The risk refers to a 10-year risk of CVD.

45. The Growing Burden of Risk from High Blood Pressure, Cholesterol, and Bodyweight

Table 45.5: Incremental Cost-Effectiveness Ratios of a Multidrug Regimen by World Bank Region Compared with a Baseline of No Drug Treatment (2001 US$/DALY)

Chapter Sections

Figures

Boxes

Tables